[go: up one dir, main page]

CR20210307A - NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312) - Google Patents

NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312)

Info

Publication number
CR20210307A
CR20210307A CR20210307A CR20210307A CR20210307A CR 20210307 A CR20210307 A CR 20210307A CR 20210307 A CR20210307 A CR 20210307A CR 20210307 A CR20210307 A CR 20210307A CR 20210307 A CR20210307 A CR 20210307A
Authority
CR
Costa Rica
Prior art keywords
derivatives
sos1
inhibitors
novel
pyridopyrimidinones
Prior art date
Application number
CR20210307A
Other languages
English (en)
Inventor
Christiane Kofink
Markus Frank
Annika Gille
Markus Ostermeier
Juergen Ramharter
Marco Hans Hofmann
Stefan Goepper
Tobias Wunberg
Anke Baum
Dorothea Ingrid RUDOLPH
Michael Gmachl
Fabio Savarese
Heinz Stadtmueller
Marco Santagostino
Julian Wippich
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20210307A publication Critical patent/CR20210307A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención abarca compuestos de fórmula <strong>(I) donde los grupos <strong>R<sup>1</sup></strong> a <strong>R<sup>4</sup></strong>, <strong>A</strong> y <strong>p </strong>tienen los significados dados en las reivindicaciones y la memoria descriptiva, su uso como inhibidores de SOS1, composiciones farmacéuticas que contienen compuestos de esta clase y su uso como medicamentos/usos médicos, especialmente como agentes para el tratamiento y/o la prevención de enfermedades oncológicas.</strong>
CR20210307A 2017-12-21 2018-12-20 NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312) CR20210307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209865 2017-12-21
PCT/EP2018/086197 WO2019122129A1 (en) 2017-12-21 2018-12-20 Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors

Publications (1)

Publication Number Publication Date
CR20210307A true CR20210307A (es) 2021-07-27

Family

ID=60781991

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20200312A CR20200312A (es) 2017-12-21 2018-12-20 Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CR20210307A CR20210307A (es) 2017-12-21 2018-12-20 NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20200312A CR20200312A (es) 2017-12-21 2018-12-20 Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1

Country Status (35)

Country Link
US (2) US10829487B2 (es)
EP (2) EP3728254B1 (es)
JP (1) JP7189956B2 (es)
KR (1) KR102746913B1 (es)
CN (1) CN111372932B (es)
AR (1) AR114164A1 (es)
AU (1) AU2018390927B2 (es)
BR (1) BR112020010123A2 (es)
CA (1) CA3085835A1 (es)
CL (2) CL2020001501A1 (es)
CO (1) CO2020007218A2 (es)
CR (2) CR20200312A (es)
DK (1) DK3728254T3 (es)
EA (1) EA202091491A1 (es)
EC (1) ECSP20040257A (es)
ES (1) ES2944306T3 (es)
FI (1) FI3728254T3 (es)
HR (1) HRP20230400T1 (es)
HU (1) HUE062076T2 (es)
IL (1) IL275379B2 (es)
JO (1) JOP20200154A1 (es)
LT (1) LT3728254T (es)
MA (1) MA51290A (es)
MX (1) MX2020006438A (es)
PE (1) PE20210163A1 (es)
PH (1) PH12020550786A1 (es)
PL (1) PL3728254T3 (es)
PT (1) PT3728254T (es)
RS (1) RS64167B1 (es)
SA (1) SA520412278B1 (es)
SG (1) SG11202005881YA (es)
SI (1) SI3728254T1 (es)
TW (1) TWI810230B (es)
UA (1) UA126173C2 (es)
WO (1) WO2019122129A1 (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62818B1 (sr) 2017-10-18 2022-02-28 Incyte Corp Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma
FI3728254T3 (fi) * 2017-12-21 2023-05-05 Boehringer Ingelheim Int Bentsyyliaminosubstituoidut pyridopyrimidinonit ja johdannaiset SOS1-estäjinä
FI3847175T3 (fi) 2018-09-05 2024-03-22 Incyte Corp Fosfoinositidi-3-kinaasin (pi3k) inhibiittorin kiteisiä muotoja
AU2020296914A1 (en) 2019-06-19 2021-12-23 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN115315424A (zh) * 2019-10-15 2022-11-08 拜耳公司 2-甲基-氮杂-喹唑啉
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
SMT202400273T1 (it) 2019-11-29 2024-09-16 Lupin Ltd Composti triciclici sostituiti
AU2020405170A1 (en) * 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
CN113045565A (zh) * 2019-12-27 2021-06-29 微境生物医药科技(上海)有限公司 新型K-Ras G12C抑制剂
JP7642647B2 (ja) 2019-12-27 2025-03-10 ルピン・リミテッド 置換三環式化合物
US20230101312A1 (en) * 2020-02-24 2023-03-30 Mirati Therapeutics, Inc. Sos1 inhibitors
TW202144338A (zh) * 2020-04-08 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用
CR20220614A (es) 2020-06-02 2023-05-08 Univ Vanderbilt 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
CN113801114B (zh) * 2020-06-11 2022-11-18 江苏恒瑞医药股份有限公司 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
JP2023528925A (ja) 2020-06-11 2023-07-06 江蘇恒瑞医薬股▲ふん▼有限公司 ピリドンピリミジン系誘導体、その調製方法及びその医薬的応用
JP2023531049A (ja) * 2020-06-24 2023-07-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｏｓ１阻害剤及びｋｒａｓ ｇ１２ｃ阻害剤を含む抗がん剤併用療法
CN113912608B (zh) * 2020-07-10 2023-07-14 江苏恒瑞医药股份有限公司 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
US20230265090A1 (en) * 2020-07-24 2023-08-24 Medshine Discovery Inc. Quinazoline compound
CN116194446A (zh) * 2020-08-06 2023-05-30 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
CN116209438A (zh) 2020-09-03 2023-06-02 锐新医药公司 使用sos1抑制剂治疗具有shp2突变的恶性疾病
EP4214209A1 (en) 2020-09-15 2023-07-26 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
TW202227427A (zh) 2020-09-16 2022-07-16 美商拜歐斯瑞克斯公司 Sos1蛋白降解劑、其醫藥組合物及其治療應用
CN116323623A (zh) * 2020-09-18 2023-06-23 拜耳公司 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺
AU2021367089B2 (en) 2020-10-20 2024-10-17 Shanghai Zelgen Pharma.Tech Co., Ltd. Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof
WO2022105921A1 (zh) * 2020-11-21 2022-05-27 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
TW202241885A (zh) 2020-12-22 2022-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｓｏｓ１抑制劑及其用途
CN114685487B (zh) * 2020-12-27 2024-04-19 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
EP4281078A1 (en) * 2021-01-19 2023-11-29 Lupin Limited Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
WO2022160931A1 (zh) * 2021-01-28 2022-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
WO2022161461A1 (zh) * 2021-01-29 2022-08-04 江苏先声药业有限公司 Sos1抑制剂及其制备方法和应用
CN114436976B (zh) * 2021-01-29 2023-07-11 石药集团中奇制药技术（石家庄）有限公司 一种新型喹唑啉类衍生物及其制备和应用
CN114835719A (zh) * 2021-02-01 2022-08-02 苏州泽璟生物制药股份有限公司 取代双环并芳杂环胺类抑制剂及其制备方法和应用
CN114835703A (zh) * 2021-02-02 2022-08-02 苏州泽璟生物制药股份有限公司 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用
US20240166645A1 (en) * 2021-02-08 2024-05-23 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Pyridopyrimidinone derivative, preparation method therefor, and use thereof
CN116669738A (zh) * 2021-02-09 2023-08-29 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
WO2022171118A1 (zh) * 2021-02-10 2022-08-18 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
CN113200981A (zh) * 2021-02-10 2021-08-03 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
US11648254B2 (en) 2021-03-02 2023-05-16 Kumquat Biosciences Inc. Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling
CN117062818A (zh) * 2021-03-05 2023-11-14 南京再明医药有限公司 新型sos1抑制剂及其制备方法和应用
EP4317157A1 (en) * 2021-03-26 2024-02-07 Medshine Discovery Inc. 6-carbamate substituted heteroaryl ring derivatives
EP4313151A1 (en) 2021-03-31 2024-02-07 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
WO2022212531A1 (en) * 2021-03-31 2022-10-06 Acerand Therapeutics (Usa) Limited Pyridopyrimidinone compounds
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
CN117979966A (zh) * 2021-04-09 2024-05-03 锐新医药公司 使用sos1抑制剂和ras抑制剂治疗癌症
US20240238294A1 (en) 2021-04-09 2024-07-18 Boehringer Ingelheim International Gmbh Anticancer therapy
AU2022257621A1 (en) 2021-04-13 2023-11-23 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2022222875A1 (zh) * 2021-04-19 2022-10-27 昆药集团股份有限公司 一种苯并嘧啶三环衍生物及其制备方法和应用
WO2022223034A1 (zh) * 2021-04-23 2022-10-27 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
EP4378478A1 (en) 2021-07-27 2024-06-05 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3227026A1 (en) * 2021-08-03 2023-02-09 Evopoint Biosciences Co., Ltd. Fused ring compound, pharmaceutical composition, and application thereof
WO2023020347A1 (zh) * 2021-08-16 2023-02-23 华润医药研究院（深圳）有限公司 嘧啶并吡啶类化合物及其制备方法和医药用途
EP4389738A4 (en) * 2021-08-17 2025-01-29 Kanaph Therapeutics Inc SOS1-INHIBITOR AND USE THEREOF
WO2023030215A1 (zh) * 2021-08-30 2023-03-09 浙江海正药业股份有限公司 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN117836278A (zh) * 2021-09-02 2024-04-05 上海海和药物研究开发股份有限公司 一种sos1抑制剂、其制备方法及用途
CN115246841B (zh) * 2021-09-14 2024-02-09 北京福元医药股份有限公司 苄氨基取代的嘧啶并吡喃酮衍生物及其组合物、制剂和用途
WO2023041049A1 (zh) 2021-09-17 2023-03-23 江苏先声药业有限公司 作为sos1抑制剂的杂环化合物及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN115724844B (zh) * 2021-11-22 2024-10-18 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP2024542692A (ja) 2021-12-01 2024-11-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 環化２－アミノ－３－シアノチオフェンを含むｋｒａ分解化合物
TW202337431A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
EP4441050A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP2024545236A (ja) * 2021-12-17 2024-12-05 石薬集団中奇制薬技術（石家庄）有限公司 抗腫瘍活性を有する複素環式化合物及びその使用
EP4448526A1 (en) 2021-12-17 2024-10-23 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023125737A1 (en) * 2021-12-29 2023-07-06 Silexon Ai Technology Co., Ltd. Heterocyclic compounds and use thereof
WO2023135260A1 (en) 2022-01-14 2023-07-20 Jazz Pharmaceuticals Ireland Limited Novel amine-substituted phthalazines and derivatives as sos1 inhibitors
EP4467542A1 (en) * 2022-01-21 2024-11-27 Medshine Discovery Inc. Crystal form of allyl-containing methylpyridopyrimidine compound
WO2023143147A1 (zh) * 2022-01-28 2023-08-03 上海优理惠生医药有限公司 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
GB202203976D0 (en) 2022-03-22 2022-05-04 Jazz Pharmaceuticals Ireland Ltd Tricyclic phthalazines and derivatives as sos1 inhibitors
EP4511128A1 (en) 2022-04-20 2025-02-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
WO2023215256A1 (en) * 2022-05-03 2023-11-09 Revolution Medicines, Inc. Sos1 inhibitors and uses thereof
WO2023215257A2 (en) * 2022-05-03 2023-11-09 Revolution Medicines, Inc. Sos1 inhibitors and uses thereof
IL316768A (en) 2022-05-25 2025-01-01 Ikena Oncology Inc MEK inhibitors and their uses
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024002318A1 (zh) * 2022-07-01 2024-01-04 四川汇宇制药股份有限公司 哒嗪并吡啶酮衍生物及其用途
WO2024008185A1 (zh) * 2022-07-07 2024-01-11 武汉人福创新药物研发中心有限公司 包含sos1抑制剂的药物组合物
CN115057847B (zh) * 2022-07-26 2024-01-26 山东百启生物医药有限公司 一种4,6-二氯-5-(1,3-二氧戊环-2-基)-2-甲基嘧啶的制备方法
CN119451960A (zh) * 2022-08-05 2025-02-14 上海艾力斯医药科技股份有限公司 一种稠环化合物、其制备方法及其应用
WO2024032615A1 (zh) * 2022-08-08 2024-02-15 武汉人福创新药物研发中心有限公司 吡啶并嘧啶酮化合物的晶型、其酸式盐、其酸式盐的晶型和用途
WO2024040131A1 (en) 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
WO2024056782A1 (en) 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain
WO2024079252A1 (en) 2022-10-13 2024-04-18 Bayer Aktiengesellschaft Sos1 inhibitors
TW202448871A (zh) * 2023-02-16 2024-12-16 南韓商賽勒斯治療有限公司 作為sos1抑制劑之唑基吡啶嗒酮醯胺
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
TW202446388A (zh) 2023-04-14 2024-12-01 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025007000A1 (en) 2023-06-30 2025-01-02 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025059046A1 (en) 2023-09-11 2025-03-20 Kumquat Biosciences Inc. Sos1 inhibitors for use in the treatment of philadelphia chromosome positive blood cancers
GB2633813A (en) * 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6174899B1 (en) 1998-05-14 2001-01-16 Morton Shulman Orally administered analgesic composition comprising myfadol
MX2009010218A (es) 2007-03-23 2009-10-19 Hoffmann La Roche Derivados de aza-piridopirimidinona.
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
ES2432414T3 (es) 2008-08-12 2013-12-03 Glaxosmithkline Llc Compuestos químicos
JP2012510444A (ja) 2008-11-28 2012-05-10 ノバルティス アーゲー 治療的処置のためのＨｓｐ９０阻害剤
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
NZ630860A (en) 2009-10-29 2016-03-31 Genosco Bissubstituted pyrido[4,3-d]-pyrimindin-5-one kinase nhibitors and medical uses
BR112013013884A2 (pt) 2010-12-06 2016-09-13 Pall Corp métodos de processamento contínuo para produtos biológicos
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
IN2014MN01755A (es) * 2012-03-14 2015-07-03 Lupin Ltd
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP2970121B1 (en) 2013-03-15 2017-12-13 Araxes Pharma LLC Covalent inhibitors of kras g12c
WO2015025326A1 (en) * 2013-08-19 2015-02-26 Council Of Scientific & Industrial Research 3-(4-ethynylphenyl) pyridopyrimidinone compounds and process for preparation thereof useful as potential antic ancer agents
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016077793A1 (en) 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
WO2018115380A1 (en) 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
FI3728254T3 (fi) * 2017-12-21 2023-05-05 Boehringer Ingelheim Int Bentsyyliaminosubstituoidut pyridopyrimidinonit ja johdannaiset SOS1-estäjinä
AU2020296914A1 (en) 2019-06-19 2021-12-23 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Also Published As

Publication number Publication date
JOP20200154A1 (ar) 2020-06-18
RS64167B1 (sr) 2023-05-31
PE20210163A1 (es) 2021-01-26
TW202415656A (zh) 2024-04-16
SG11202005881YA (en) 2020-07-29
AU2018390927A1 (en) 2020-05-28
CR20200312A (es) 2020-09-11
JP2021506864A (ja) 2021-02-22
AU2018390927B2 (en) 2023-01-12
CL2021000907A1 (es) 2021-10-29
HUE062076T2 (hu) 2023-09-28
BR112020010123A2 (pt) 2020-11-10
EP3728254B1 (en) 2023-02-15
HRP20230400T1 (hr) 2023-06-23
CN111372932B (zh) 2023-11-21
CA3085835A1 (en) 2019-06-27
US20210009588A1 (en) 2021-01-14
IL275379A (en) 2020-07-30
US10829487B2 (en) 2020-11-10
KR102746913B1 (ko) 2024-12-24
PT3728254T (pt) 2023-05-02
CN111372932A (zh) 2020-07-03
EA202091491A1 (ru) 2020-11-13
MA51290A (fr) 2021-03-31
PH12020550786A1 (en) 2021-04-12
CO2020007218A2 (es) 2020-06-19
US20190194192A1 (en) 2019-06-27
MX2020006438A (es) 2020-09-17
EP4219493A1 (en) 2023-08-02
ES2944306T3 (es) 2023-06-20
LT3728254T (lt) 2023-05-10
CL2020001501A1 (es) 2020-11-13
SI3728254T1 (sl) 2023-06-30
AR114164A1 (es) 2020-07-29
UA126173C2 (uk) 2022-08-25
WO2019122129A1 (en) 2019-06-27
JP7189956B2 (ja) 2022-12-14
ECSP20040257A (es) 2020-08-31
DK3728254T3 (da) 2023-06-06
FI3728254T3 (fi) 2023-05-05
IL275379B2 (en) 2023-06-01
SA520412278B1 (ar) 2022-08-17
US11814380B2 (en) 2023-11-14
EP3728254A1 (en) 2020-10-28
TWI810230B (zh) 2023-08-01
KR20200111163A (ko) 2020-09-28
TW201938557A (zh) 2019-10-01
PL3728254T3 (pl) 2023-06-12

Similar Documents

Publication Publication Date Title
PH12020550786A1 (en) Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
SA518391307B1 (ar) مركبات ومشتقات سبيرو [ إندول -3، 2- بيروليدين h3] أون جديدة على هيئة مثبطات الدقيقة المزدوجة للفأر(1h)2 بي2-53
PH12018500259A1 (en) Muscarinic agonists
PH12017500453B1 (en) Spirocyclic inhibitors of cathepsin c
MX372997B (es) Compuestos de aminopirimidina como inhibidores de jak.
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
NZ708593A (en) Novel pyrazole derivative
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
MX378732B (es) Formas solidas novedosas
PH12015502365B1 (en) Bace1 inhibitors
GEP20196961B (en) 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
PH12018500378B1 (en) Novel annelated phenoxyacetamides
NZ702254A (en) 5-amino[1,4]thiazines as bace 1 inhibitors
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX382175B (es) Composiciones de profármaco de monometilfumarato
PH12017501668A1 (en) Bace1 inhibitors
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
GB2553685A (en) Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors